Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Faron Pharmaceuticals

0.51 EUR

-2.88 %

5,677 following
Corporate customer

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

-2.88 %
-16.45 %
-74.70 %
-73.39 %
-75.40 %
-75.06 %
-85.05 %
-86.40 %
-84.88 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
100.81M EUR
Turnover
256.07K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Buy
Target price
Updated
12.03.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 12.03.2026

Latest extensive report

Released: 23.08.2022

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4.5.
2026

General meeting '26

26.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
It must be remembered that the Jalkanen family is a truly significant owner and the face of the company. If they don’t participate in the offering, how could anyone expect others to do so? After all, they have the best possible insight into how the company is doing. That subscription...
7 hours ago
by Kilohai80
12
One can always speculate on how the offering should have been marketed. I don’t even know if there are specific rules, such as whether you have to disclose how many shares will be issued, etc. Personally, what I did was sell a portion when the subscription rights were issued. Tax...
6 hours ago
by MyrtsiZzz
11
The announcement stated: The Company clarifies the information provided in the Prospectus regarding a potential directed share issue as follows: Separate from the Share Issue, the Company may also issue a total of up to 19,296,473 shares in a directed share issue at a subscription...
6 hours ago
by Vino Pino
8
If HCM’s hyenas (who remembers the nickname used for IPF?) vacuum up the unsubscribed shares, it would be the worst-case scenario for the owners—not to subscribe, even if they intended to buy from the exchange anyway. There would be less dilution, if I’ve understood correctly. Usually...
8 hours ago
by Vino Pino
8
The continuation of this horror scenario could be that the share price is dumped and the next funding round is carried out at such a low price that the current shareholders’ holdings effectively vanish into thin air (cf. Bioretec). A Faron shareholder should hope for a takeover bid...
7 hours ago
by minisijoittaja
7
You are quite right about that, but with Faron, HCM’s ownership stake could at worst become so large that there is no reasonable way to dump those shares onto the market. In my opinion, the most horrifying scenario would be if HCM ends up with even 10 million shares from the offering...
7 hours ago
6
Yes, HCM’s underwriting commitment is cold hard cash, and those convertible bonds won’t be settled in the share issue. The conversion price of the convertible bond will indeed drop to a maximum of 0.5 euros in connection with the issue, which is a massive deterioration compared to...
7 hours ago
5
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.